What we Know so far about Myxovirus Resistance Protein A (MxA) as a Biomarker of Interferon-Beta Therapy in Patients with Multiple Sclerosis: a Systematic Review
Men's Health Journal,
Vol. 3 No. 1 (2019),
13 Farvardin 2019
,
Page e19
https://doi.org/10.22037/mhj.v3i1.33124
Abstract
Introduction: Multiple sclerosis (MS) is one of the most common neurological disabling diseases in human societies with no complete cure. IFN-β has been proven to be an important advance in the MS treatment, but early identification of treatment failure is its major concern. Some researches revealed that MxA is an appropriate biomarker for predicting response to IFN-β, so we performed this study to evaluate the relationship between MxA level and response to INF- β treatment.Methods: International and internal databases were searched using “MxA”, “Myxovirus resistance protein A”, “IFN-β”, “interferon Beta”, “multiple sclerosis” and “MS keywords until October 2019. Inclusion criteria were original studies considering the MxA assays in MS patients under IFN-β therapy. Some reported cut-offs from partially the same settings (7 studies) were pooled using the weighted average. Finally, the overall statements of the included studies were compared and discussed to obtain a comprehensive conclusion about the clinical value of MxA assays in patient monitoring and designing their treatment plan. Results: A total of 456 articles were identified. The Screening was led to exclusion of 427 articles. Finally, 28 original studies met the inclusion criteria for this systematic review. Almost all studies have concluded that the MxA is significantly correlated with response to IFN-β therapy and also MxA expression is under the direct effect of Neutralizing antibody (NAb) against IFN-β. Reported cut-offs for MxA ranged from 3.3 to 6.3 NR and the weighted average of them was estimated to be 4.1 NR. Conclusion: It could be suggested that in patients under IFN-β therapy with an active disease which doesn’t fulfill the criteria for the breakthrough disease, MxA level can help to determine whether to continue the drug and follow up a patient or change the treatment regimen.
How to Cite
References
Dilokthornsakul, P., et al., Multiple sclerosis prevalence in the United States commercially insured population. Neurology, 2016. 86(11): p. 1014-1021.
Garcia-Montojo, M., et al., Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients. Journal of neurovirology, 2007. 13(6): p. 504-512.
Alajbegovic, A., et al., Interferon Treatment of Multiple Sclerosis. Materia socio-medica, 2012. 24(1): p. 38.
Hegen, H., M. Auer, and F. Deisenhammer, Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β. Expert opinion on drug metabolism & toxicology, 2015. 11(12): p. 1803-1819.
Pachner, A.R., et al., MxA gene expression analysis as an interferon-β bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Molecular Diagnosis, 2003. 7(1): p. 17-25.
Bertolotto, A., et al., Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology, 2003. 60(4): p. 634-639.
Massart, C., et al., Determination of interferon beta neutralizing antibodies in multiple sclerosis: Improvement of clinical sensitivity of a cytopathic effect assay. Clinica Chimica Acta, 2008. 391(1-2): p. 98-101.
Haller, O. and G. Kochs, Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. Journal of Interferon & Cytokine Research, 2011. 31(1): p. 79-87.
Pietrzak, A., et al., A long-term follow-up study on biochemical and clinical biomarkers of response to interferon beta-1b treatment in relapsing-remitting multiple sclerosis. Advances in Clinical and Experimental Medicine, 2020. 29(7): p. 841-851.
Fattahi, M., et al., MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis. Multiple sclerosis and related disorders, 2019. 35: p. 241-245.
Taheri M, Mirinezhad M, Omrani MD, Sajjadi E, Inoko H, Sayad A. Inverse relation between MxA gene expression and age in multiple sclerosis patients reveals a gender difference in response to interferon therapy. Iranian Journal of Allergy, Asthma and Immunology. 2017 Feb 25;16(1):21-7.
Matas, E., et al., MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients. Journal of neuroimmunology, 2016. 291: p. 73-77.
Matas, E., et al., Absence of MxA induction is related to a poor clinical response to interferon beta treatment in multiple sclerosis patients. Journal of neurology, 2016. 263(4): p. 722-729.
Juntunen, E., et al., Lateral flow immunoassay with upconverting nanoparticle‐based detection for indirect measurement of interferon response by the level of MxA. Journal of medical virology, 2017. 89(4): p. 598-605.
Matas, E., et al., Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients. PloS one, 2014. 9(11): p. e112758.
Cakal, B., et al., BAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients. Journal of Immunoassay and Immunochemistry, 2014. 35(4): p. 398-411.
Serana, F., et al., MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients. PLoS One, 2014. 9(4): p. e94794.
Hermanrud, C., et al., Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. Journal of Interferon & Cytokine Research, 2014. 34(7): p. 498-504.
Malucchi, S., et al., One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. Journal of neurology, 2011. 258(5): p. 895-903.
Garcia‐Montojo, M., et al., Neutralizing antibodies, MxA expression and MMP‐9/TIMP‐1 ratio as markers of bioavailability of interferon‐beta treatment in multiple sclerosis patients: a two‐year follow‐up study. European journal of neurology, 2010. 17(3): p. 470-478.
Zanotti, C., et al., Transfer of myxovirus-protein-A mRNA assay for interferon-β bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. Clinical Chemistry and Laboratory Medicine (CCLM), 2010. 48(9): p. 1235-1238.
Van der Voort, L., et al., Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. Neurology, 2010. 75(14): p. 1228-1233.
Van Der Voort LF, Visser A, Knol DL, Oudejans CB, Polman CH, Killestein J. Lack of interferon‐beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. European journal of neurology. 2009 Sep;16(9):1049-52.
Hesse, D., F. Sellebjerg, and P.S. Sorensen, Absence of MxA induction by interferon β in patients with MS reflects complete loss of bioactivity. Neurology, 2009. 73(5): p. 372-377.
Pachner, A.R., et al., Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology, 2009. 73(18): p. 1493-1500.
Millonig A, Dressel A, Bahner D, Bitsch A, Bogumil T, Elitok E, Kitze B, Tumani H, Weber F, Gneiss C, Deisenhammer F. MxA protein–an interferon beta biomarker in primary progressive multiple sclerosis patients. European journal of neurology. 2008 Aug;15(8):822-6.
Vallittu, A.M., et al., MxA protein assay for optimal monitoring of IFN‐β bioactivity in the treatment of MS patients. Acta neurologica scandinavica, 2008. 118(1): p. 12-17.
Malucchi, S., et al., Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology, 2008. 70(13 Part 2): p. 1119-1127.
Capra, R., et al., IFNβ bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. Journal of neuroimmunology, 2007. 189(1-2): p. 102-110.
Gilli, F., et al., Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Multiple Sclerosis Journal, 2006. 12(1): p. 47-57.
Pachner, A.R., et al., The importance of measuring IFNβ bioactivity: monitoring in MS patients and the effect of anti-IFNβ antibodies. Journal of neuroimmunology, 2005. 166(1-2): p. 180-188.
Bertolotto, A., et al., Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. Journal of Neurology, Neurosurgery & Psychiatry, 2004. 75(9): p. 1294-1299.
Vallittu, A.-M., et al., Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients. Neurology, 2002. 58(12): p. 1786-1790.
Bertolotto, A., et al., Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. Journal of immunological methods, 2001. 256(1-2): p. 141-152.
Kracke, A., et al., Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology, 2000. 54(1): p. 193-193.
Deisenhammer, F., et al., Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology, 1999. 52(6): p. 1239-1239.
Yamout B, Alroughani R, Al-Jumah M, Khoury S, Abouzeid N, Dahdaleh M, Alsharoqi I, Inshasi J, Hashem S, Zakaria M, ElKallab K. Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Current medical research and opinion. 2013 Jun 1;29(6):611-21.
- Abstract Viewed: 124 times
- pdf Downloaded: 66 times